Merck
14 articles
Industry NewsModerna / MerckBioSpace
Moderna Returns to Profit as Cancer Vaccine Heads to a Filing
- Third-quarter revenue rose about 29% to $1.3 billion on global COVID vaccine sales, and full-year growth guidance was lifted to 15–25%. Analysts questioned how much reflects 2027 deliveries shipped early.
- Intismeran, with Merck, showed a 42% lower risk of recurrence or death in melanoma alongside Keytruda; a BLA is planned by year-end with a decision expected in 2027, and a renal cancer Phase 2 is next.
- The norovirus vaccine missed its early Phase 3 bar, so no further cohort will be enrolled this season.
Profit this quarter is seasonal COVID timing; the real story is that Moderna's identity is shifting to oncology, with intismeran its first potential approval outside respiratory vaccines. Merck shares the economics, and the open question is the manufacturing and reimbursement model for a bespoke product at launch scale.
Industry NewsMerck / ModernaBioSpace
Merck and Moderna show personalized melanoma vaccine can be made for nearly every trial patient
- In the Phase 3 INTerpath-001 melanoma study (1,137 patients), intismeran autogene plus Keytruda cut recurrence or death risk by 42% (HR 0.58).
- A manufactured vaccine reached 99% of patients assigned to it; 82% of screened patients had enough tumor tissue.
- Of those, 91% received the full set of up to 34 neoantigens, and the rest still got a shot with fewer targets.
- Merck and Moderna are also testing it in kidney, lung and bladder cancer.
The efficacy number gets the headlines, but the 99% manufacturing success rate is what a payer and a competitor should study. Bespoke-per-patient products have usually died on logistics, and this one scaled across 1,137 patients. With Keytruda facing patent expiry, Merck is building a follow-on franchise on top of its own anchor drug, and Moderna gets a credible path beyond respiratory vaccines.
Industry NewsFormycon / Zydus Lifesciences / MerckBioPharma Dive
Keytruda biosimilars near FDA review, but payer dynamics and low uptake loom
- The FDA accepted Formycon's FYB206, the first publicly disclosed Keytruda biosimilar filing, in October 2026; approval could come as early as Q3 2027, ahead of key patent expiries starting in 2028.
- Zydus will commercialize FYB206 in the US and Canada, and the FDA reportedly agreed a pathway without a comparative phase 3 efficacy trial; about a dozen other candidates are in development.
- Obstacles include uncertainty over which of Keytruda's 30-plus indications will be covered, PBM formulary preference for high-rebate brands, and biosimilar share still under 20%; Keytruda earned Merck $31.7 billion in 2025.
A skipped comparative phase 3 lowers the cost of entering, but it does nothing for the harder problem: Merck's rebate leverage with PBMs. Biosimilar share under 20% suggests price cuts alone don't move formularies. Watch the label scope FDA grants FYB206 and whether Zydus pairs it with an aggressive net-price or private-label PBM arrangement.
Industry NewsMerck / Kelun-BiotechEndpoints News
Merck's R&D Chief Says Breadth Gives sac-TMT the Edge in the TROP2 ADC Race
- In an Endpoints interview, Merck R&D head Dean Li argued the company outflanked rivals on next-generation oncology by pushing sac-TMT, its Kelun-licensed TROP2 ADC, into a wide set of indications.
- He pointed to the gynecologic and gastric cancer programs as where the drug has an advantage over competing TROP2 ADCs.
- Context: sac-TMT recently posted a survival benefit in a Phase 3 endometrial cancer trial, which has FDA priority review.
Li is selling breadth as the moat: with TROP2 ADCs converging on lung and breast, Merck is trying to own tumor types where rivals are absent and where Keytruda combinations are natural. It is a sensible hedge against the Keytruda patent cliff, but the claim is an executive's own read, and it only holds if the gynecologic and gastric trials keep delivering.
Industry NewsMerck / Kelun-BiotechBioSpace
Sac-TMT Beats Chemo on Survival in Endometrial Cancer, a First for a TROP2 ADC
- In the Phase 3 TroFuse-005 trial (about 776 patients), the TROP2 ADC sac-TMT from Merck and Kelun-Biotech outperformed chemotherapy in previously treated advanced or recurrent endometrial cancer.
- Median overall survival reached 19.0 versus 12.1 months, and progression-free survival 7.2 versus 3.9 months.
- Severe treatment-related adverse events were more common with the ADC (54.4% vs 41.4%). The FDA has granted priority review.
A 6.9-month overall survival gain over chemotherapy is a strong result in a TROP2 field where Gilead and Daiichi Sankyo/AstraZeneca already compete, and it gives sac-TMT randomized survival data to lean on. The 13-point gap in severe adverse events will shape its positioning. For Merck, it shows a China-originated ADC moving toward the center of its oncology pipeline.
Industry NewsModerna / MerckBioPharma Dive
Merck and Moderna's mRNA melanoma vaccine clears the bar at ESMO, but Moderna's stock drops
- Adjuvant intismeran plus Keytruda cut the relative risk of recurrence or death versus Keytruda alone, with a similar cut in distant spread, at about two years' median follow-up.
- Side effects were broadly similar between arms apart from more fever and injection-site pain; discontinuations for adverse events were slightly higher with the vaccine.
- Moderna's shares fell sharply after the early data leak and presentation; Merck's barely moved. Studies in lung, bladder and kidney cancer continue.
The result landed at the low end of what analysts wanted, and the benefit looks smaller than the Phase 2 signal. Approval looks plausible; the harder question is how many more tumor types a personalized, patient-by-patient manufacturing model can serve. The kidney and lung readouts will say whether this is a platform or a one-indication product.
Industry NewsMerck / ModernaSTAT News
Merck and Moderna say their mRNA cancer vaccine plan still needs a lot of exploring
- At the STAT Summit, Moderna's Stephen Hoge and Merck's Dean Li discussed pairing Keytruda with personalized mRNA cancer vaccines.
- Both executives framed the first positive results as a start, with much left to work out.
- This summary rests on the article's teaser, not the full text.
Pairing a personalized vaccine with Keytruda protects Merck's franchise as PD-1 exclusivity ages, so Merck has a strategic reason beyond the science. The executives' caution about what comes next is telling: the open questions are tumor types, dosing settings and manufacturing scale. Rivals with other neoantigen approaches should read it as a bar to clear.
Industry NewsMerckSTAT News
Dutch court halts Merck's subcutaneous Keytruda in several European countries
- STAT reports a Dutch court ordered Merck to stop manufacturing and marketing its subcutaneous Keytruda formulation in several European countries.
- Only the public lede was readable, so the plaintiff, grounds and scope are unverified here.
Subcutaneous Keytruda is Merck's main defense against the coming pembrolizumab biosimilar era, so any European delay hits that lifecycle plan directly. How long the order lasts and whether it is overturned on appeal matters more than the headline, and the case echoes the broader fight over SC hyaluronidase formulation patents.
Industry NewsMerck / SciBrunch TherapeuticsEndpoints News
Merck pays $400M upfront for SciBrunch's preclinical KRAS G12D inhibitor
- Merck took exclusive worldwide rights to SPR2015, an oral preclinical KRAS G12D (ON) inhibitor from Shanghai-based SciBrunch.
- SciBrunch gets $400M upfront, with total potential value of $2.13B across milestones.
- The deal has already closed.
$400M upfront for a preclinical asset is striking and shows how heated the KRAS G12D race has become, with China-originated assets now priced like clinical ones. For Merck it's a late entry into a field where it needs a differentiated ON-state profile, and the one to watch is first-in-human data.
Industry NewsMerckSTAT News
Merck Pulls Recarbrio From the U.S. Market, Leaving No Late-Stage Antibacterial Programs
- Merck is discontinuing Recarbrio, its reserve-use antibiotic combination, in the U.S. as part of a portfolio review, and says the move is unrelated to safety or quality.
- Approved seven years ago for hospital-acquired pneumonia and complicated urinary and abdominal infections with few options, it leaves Merck with only mature antibiotics and, per trade reports, no antibacterial programs in Phase II or later.
Reserve antibiotics are meant to be used sparingly, which caps sales, and a big pharma walking away from one confirms the broken economics of anti-infective launches. Small biotechs will read this as a warning, and policymakers will cite it in the case for pull incentives. The open question is whether Merck out-licenses the product or simply sunsets it.
Industry NewsMerck / SciBrunch TherapeuticsEndpoints News
Merck Licenses China-Origin KRAS G12D Inhibitor SPR2015 for $400M Upfront
- Merck & Co. entered an exclusive global license agreement with Shanghai-based SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D molecular-glue inhibitor.
- SciBrunch will receive $400 million upfront, with total deal value up to $2.13 billion including milestone payments.
- The deal reflects a growing trend of U.S. pharma companies in-licensing China-originated oncology assets.
This plugs Merck's biggest KRAS gap: everyone's crowded into G12C, but G12D — more common in pancreatic and colorectal cancer — has stayed stubbornly undrugged with covalent chemistry. A molecular-glue approach, if it works, sidesteps that entirely. The modest 19% upfront-to-total ratio signals early-stage derisking, not a validated asset — expect Western rivals to scramble for the remaining China-origin G12D candidates.
Industry NewsMerck / Daiichi SankyoEndpoints News
Merck, Daiichi Sankyo Withdraw FDA Application for Ifinatamab Deruxtecan in Lung Cancer
- Merck & Co. and Daiichi Sankyo voluntarily withdrew their FDA BLA for ifinatamab deruxtecan, a B7-H3-targeted ADC, in previously treated ES-SCLC.
- FDA feedback indicated Phase 2 data didn't support accelerated approval, marking the alliance's second pullback for the drug after an earlier lung-toxicity-related clinical hold.
- The companies continue the Phase 3 IDeate-Lung02 confirmatory trial and other Phase 3 studies in prostate and esophageal cancer.
A second stumble for the same molecule is a real signal, but it's about ifinatamab deruxtecan's timeline, not the Merck-Daiichi deal's overall health — this alliance is bigger than one BLA. Withdrawing rather than fighting for a contested approval is the disciplined move, protecting IDeate-Lung02's confirmatory data package. But every added year gives rival B7-H3 ADC programs room to catch up.
Industry NewsMerckFiercePharma
FDA Widens Winrevair's Reach to Newly Diagnosed PAH Patients
- The FDA approved an updated label for Merck's Winrevair (sotatercept-csrk) incorporating Phase 3 HYPERION trial data in adults recently diagnosed with pulmonary arterial hypertension.
- The trial found that adding Winrevair to background therapy substantially lowered the risk of clinical worsening events versus placebo.
- The update supports earlier use of Winrevair in the PAH treatment journey, marking the drug's third positive Phase 3 study.
Earlier-line positioning is what actually moves Winrevair's addressable market: shifting from a background-therapy add-on to newly diagnosed patients sets up a genuine first-line challenge to United Therapeutics' oral PAH franchise, and a third consecutive positive Phase 3 makes this look like a durable platform rather than a one-hit trial.
Industry NewsMerckFierce Biotech
Merck Cuts 54 More Jobs at NJ Headquarters Amid Cost-Cutting Push
- Merck & Co. filed a WARN notice announcing plans to cut approximately 54 jobs at its Rahway, New Jersey headquarters, with the reductions taking effect in two phases on December 11, 2026 and January 4, 2027.
- The cuts add to a string of 2026 workforce reductions at the Rahway site, including an earlier round of roughly 88 positions eliminated in September, bringing New Jersey job losses this year to more than 140.
- The move is part of Merck's broader multiyear restructuring, launched in 2025, aimed at cutting roughly $3 billion in annual costs by the end of 2027.
- Merck has framed the cost-cutting as preparation for the eventual loss of patent exclusivity on Keytruda, its top-selling cancer immunotherapy, while continuing to invest in newer pipeline programs.
Fifty-four jobs at Rahway barely moves the needle against a $3 billion, ~6,000-role restructuring — but the drip-feed pattern is the real story. This is at least the second Rahway tranche in 2026 alone, part of a rolling cadence that keeps each WARN filing small enough to avoid a single damaging headline, even as the cumulative New Jersey total quietly tops 140 for the year. That looks like a deliberate IR strategy: stagger the pain, let every notice read as routine. Underneath sits the actual driver — Keytruda's 2028 patent cliff, the largest LOE event in oncology, pushing Merck to reshape its cost base years ahead of the revenue hit rather than scrambling once exclusivity lapses. Expect more of these incremental announcements through 2027.